Lymphoma - small lymphocytic lymphoma

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

As this program is now on the general schedule, from 1 January 2022 this page is for informational purposes only.

Patient eligibility

The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with SLL.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib.

Authority applications

Applying for initial treatment

To apply for initial authority approval to prescribe PBS subsidised idelalisib to treat SLL either:

Applying for continuing treatment

To apply for continuing authority approval to prescribe PBS subsidised idelalisib to treat SLL either:

More information

Call the PBS authority approvals line for further information.

Page last updated: 3 March 2022